- Home
- FLYE vs CANF Comparison
FLYE vs CANF Comparison
Compare FLYE & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLYE | CANF |
|---|---|---|
| Founded | 2018 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 4.8M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | FLYE | CANF |
|---|---|---|
| Price | $6.61 | $0.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.25 |
| AVG Volume (30 Days) | 1.1M | ★ 1.5M |
| Earning Date | 12-18-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,966,391.00 | $560,000.00 |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.83 | $0.25 |
| 52 Week High | $166.00 | $2.33 |
Technical Indicators
Market Signals| Indicator | FLYE | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 49.15 | 31.31 |
| Support Level | $6.06 | $0.26 |
| Resistance Level | $8.26 | $0.30 |
| Average True Range (ATR) | 1.39 | 0.03 |
| MACD | -0.44 | -0.00 |
| Stochastic Oscillator | 3.10 | 4.78 |
Price Performance
Historical ComparisonAbout FLYE Fly-E Group Inc.
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).